LL-37 results: what to expect and when

A human defense peptide with mixed topical wound-trial results and no established injection regimen.

Also called: LL37, Cathelicidin LL-37, hCAP18/LL-37.

Anti-inflammatory and antimicrobial peptides · Human cathelicidin antimicrobial and immune-signaling peptide.

Six intervention studies: three topical wound trials, one registry-only tumor-injection trial, and two engineered-bacteria oral studies, including one preprint.

Key studies

  • Phase I/II wound dose trial: The two lower strengths improved early healing measures; 3.2 mg/mL did not. (source)
  • HEAL LL-37: Neither strength improved complete wound closure overall. (source)
  • Diabetic foot-ulcer cream: LL-37 improved granulation, but wound-area and bacterial outcomes did not differ significantly. (source)
  • Phase I/II melanoma injections: Posted results describe three treated patients; this is far too small to establish cancer benefit. (source)
  • Oral bacterial-delivery pilot: The uncontrolled preprint reported symptom improvements and no adverse reactions. (source)
  • Oral bacterial delivery in COVID: Viral clearance did not differ overall; an early-treatment subgroup had a signal. (source)

Related to LL-37

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.